Platelet function and activation markers in primary hypercholesterolemia treated with PCSK9 monoclonal antibody: a 12-month follow-up

ConclusionBesides markedly lowering LDL-c levels, our results suggest that HC patients benefit from PCSK9 mAb treatment also for reducing platelet reactivity and increasing platelet sensitivity to the inhibitory effects of aspirin. These effects on platelets could play a role in the reduction of CV event incidence in patients treated with PCSK9-inhibitors.
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research